LLY vs MRK
LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies. MRK: Merck & Co. is a leading global biopharmaceutical firm dedicated to delivering life-saving vaccines and innovative therapeutic medicines for major disease areas.
Side-by-side fundamentals
| Metric | LLY | MRK | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $1,255.40 | $152.55 | |
| Market cap as of 2026-08-24 | $1.18T | $376.4B | |
| P/E as of 2026-08-24 | 43.17 | 103.86 | LLY lower |
| PEG as of 2026-08-24 | 1.48 | 4.91 | LLY lower |
| Net margin as of 2026-08-24 | +33.5% | +4.8% | LLY higher |
| Gross margin as of 2026-08-24 | +83.4% | +77.3% | LLY higher |
| Operating margin as of 2026-08-24 | +42.2% | +9.6% | LLY higher |
| ROE as of 2026-08-24 | +92.6% | +17.9% | LLY higher |
| ROA as of 2026-08-24 | +22.0% | +7.0% | LLY higher |
| Debt / equity as of 2026-08-24 | 1.62 | 1.07 | MRK lower |
| Revenue growth (YoY) as of 2026-08-24 | +49.6% | +4.6% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +31.7% | +3.1% | LLY higher |
| Dividend yield as of 2026-08-24 | +0.8% | +2.9% | MRK higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-24 | 0.46 | 0.22 | |
| 1-year return as of 2026-08-21 close | +76.9% | +77.2% | MRK higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.